Equities Analysts Issue Forecasts for LXRX Q1 Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Lexicon Pharmaceuticals in a report issued on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings of ($0.09) per share for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q2 2025 earnings at ($0.09) EPS and Q3 2025 earnings at ($0.10) EPS.

Several other brokerages have also recently weighed in on LXRX. Leerink Partnrs downgraded Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Leerink Partners reiterated a “market perform” rating and issued a $1.00 price target (down from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. Piper Sandler dropped their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.67.

Lexicon Pharmaceuticals Stock Up 6.6 %

LXRX stock opened at $0.39 on Monday. The company has a market capitalization of $96.48 million, a price-to-earnings ratio of -0.52 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. The business’s 50 day moving average price is $0.73 and its two-hundred day moving average price is $1.13. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.83.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The company had revenue of $26.55 million for the quarter, compared to analysts’ expectations of $6.48 million.

Institutional Trading of Lexicon Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its stake in shares of Lexicon Pharmaceuticals by 71.2% in the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 13,246 shares in the last quarter. Wellington Management Group LLP lifted its position in Lexicon Pharmaceuticals by 2.1% in the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company’s stock valued at $552,000 after acquiring an additional 15,249 shares in the last quarter. Arizona State Retirement System boosted its stake in Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 16,136 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Lexicon Pharmaceuticals by 60.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 24,615 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Lexicon Pharmaceuticals by 27.4% in the fourth quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 29,319 shares during the last quarter. 74.70% of the stock is owned by hedge funds and other institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.